PortalPublikationenMAGIC biomarkers predict long term outcomes for steroid-resi...

MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD

Standard

MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD. / Major-Monfried, Hannah; Renteria, Anne S; Pawarode, Attaphol; Reddy, Pavan; Ayuk, Francis; Holler, Ernst; Efebera, Yvonne A; Hogan, William J; Wölfl, Matthias; Qayed, Muna; Hexner, Elizabeth O; Wudhikarn, Kitsada; Ordemann, Rainer; Young, Rachel; Shah, Jay; Hartwell, Matthew J; Chaudhry, Mohammed; Aziz, Mina; Etra, Aaron; Yanik, Gregory A; Kröger, Nicolaus; Weber, Daniela; Chen, Yi-Bin; Nakamura, Ryotaro; Rösler, Wolf; Kitko, Carrie L; Harris, Andrew C; Pulsipher, Michael; Reshef, Ran; Kowalyk, Steven; Morales, George; Torres, Ivan; Özbek, Umut; Ferrara, James L M; Levine, John E.

in: BLOOD, Jahrgang 131, Nr. 25, 21.06.2018, S. 2846-2855.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Major-Monfried, H, Renteria, AS, Pawarode, A, Reddy, P, Ayuk, F, Holler, E, Efebera, YA, Hogan, WJ, Wölfl, M, Qayed, M, Hexner, EO, Wudhikarn, K, Ordemann, R, Young, R, Shah, J, Hartwell, MJ, Chaudhry, M, Aziz, M, Etra, A, Yanik, GA, Kröger, N, Weber, D, Chen, Y-B, Nakamura, R, Rösler, W, Kitko, CL, Harris, AC, Pulsipher, M, Reshef, R, Kowalyk, S, Morales, G, Torres, I, Özbek, U, Ferrara, JLM & Levine, JE 2018, 'MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD', BLOOD, Jg. 131, Nr. 25, S. 2846-2855. https://doi.org/10.1182/blood-2018-01-822957

APA

Major-Monfried, H., Renteria, A. S., Pawarode, A., Reddy, P., Ayuk, F., Holler, E., Efebera, Y. A., Hogan, W. J., Wölfl, M., Qayed, M., Hexner, E. O., Wudhikarn, K., Ordemann, R., Young, R., Shah, J., Hartwell, M. J., Chaudhry, M., Aziz, M., Etra, A., ... Levine, J. E. (2018). MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD. BLOOD, 131(25), 2846-2855. https://doi.org/10.1182/blood-2018-01-822957

Vancouver

Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E et al. MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD. BLOOD. 2018 Jun 21;131(25):2846-2855. https://doi.org/10.1182/blood-2018-01-822957

Bibtex

@article{6fd707efc72746a9aaf605758b07d067,
title = "MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD",
abstract = "Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid immunosuppression. Clinical response after 1 week of therapy often guides further treatment decisions, but long-term outcomes vary widely among centers, and more accurate predictive tests are urgently needed. We analyzed clinical data and blood samples taken 1 week after systemic treatment of GVHD from 507 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC), dividing them into a test cohort (n = 236) and 2 validation cohorts separated in time (n = 142 and n = 129). Initial response to systemic steroids correlated with response at 4 weeks, 1-year nonrelapse mortality (NRM), and overall survival (OS). A previously validated algorithm of 2 MAGIC biomarkers (ST2 and REG3α) consistently separated steroid-resistant patients into 2 groups with dramatically different NRM and OS (P < .001 for all 3 cohorts). High biomarker probability, resistance to steroids, and GVHD severity (Minnesota risk) were all significant predictors of NRM in multivariate analysis. A direct comparison of receiver operating characteristic curves showed that the area under the curve for biomarker probability (0.82) was significantly greater than that for steroid response (0.68, P = .004) and for Minnesota risk (0.72, P = .005). In conclusion, MAGIC biomarker probabilities generated after 1 week of systemic treatment of GVHD predict long-term outcomes in steroid-resistant GVHD better than clinical criteria and should prove useful in developing better treatment strategies.",
keywords = "Journal Article",
author = "Hannah Major-Monfried and Renteria, {Anne S} and Attaphol Pawarode and Pavan Reddy and Francis Ayuk and Ernst Holler and Efebera, {Yvonne A} and Hogan, {William J} and Matthias W{\"o}lfl and Muna Qayed and Hexner, {Elizabeth O} and Kitsada Wudhikarn and Rainer Ordemann and Rachel Young and Jay Shah and Hartwell, {Matthew J} and Mohammed Chaudhry and Mina Aziz and Aaron Etra and Yanik, {Gregory A} and Nicolaus Kr{\"o}ger and Daniela Weber and Yi-Bin Chen and Ryotaro Nakamura and Wolf R{\"o}sler and Kitko, {Carrie L} and Harris, {Andrew C} and Michael Pulsipher and Ran Reshef and Steven Kowalyk and George Morales and Ivan Torres and Umut {\"O}zbek and Ferrara, {James L M} and Levine, {John E}",
note = "Copyright {\textcopyright} 2018 American Society of Hematology.",
year = "2018",
month = jun,
day = "21",
doi = "10.1182/blood-2018-01-822957",
language = "English",
volume = "131",
pages = "2846--2855",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "25",

}

RIS

TY - JOUR

T1 - MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD

AU - Major-Monfried, Hannah

AU - Renteria, Anne S

AU - Pawarode, Attaphol

AU - Reddy, Pavan

AU - Ayuk, Francis

AU - Holler, Ernst

AU - Efebera, Yvonne A

AU - Hogan, William J

AU - Wölfl, Matthias

AU - Qayed, Muna

AU - Hexner, Elizabeth O

AU - Wudhikarn, Kitsada

AU - Ordemann, Rainer

AU - Young, Rachel

AU - Shah, Jay

AU - Hartwell, Matthew J

AU - Chaudhry, Mohammed

AU - Aziz, Mina

AU - Etra, Aaron

AU - Yanik, Gregory A

AU - Kröger, Nicolaus

AU - Weber, Daniela

AU - Chen, Yi-Bin

AU - Nakamura, Ryotaro

AU - Rösler, Wolf

AU - Kitko, Carrie L

AU - Harris, Andrew C

AU - Pulsipher, Michael

AU - Reshef, Ran

AU - Kowalyk, Steven

AU - Morales, George

AU - Torres, Ivan

AU - Özbek, Umut

AU - Ferrara, James L M

AU - Levine, John E

N1 - Copyright © 2018 American Society of Hematology.

PY - 2018/6/21

Y1 - 2018/6/21

N2 - Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid immunosuppression. Clinical response after 1 week of therapy often guides further treatment decisions, but long-term outcomes vary widely among centers, and more accurate predictive tests are urgently needed. We analyzed clinical data and blood samples taken 1 week after systemic treatment of GVHD from 507 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC), dividing them into a test cohort (n = 236) and 2 validation cohorts separated in time (n = 142 and n = 129). Initial response to systemic steroids correlated with response at 4 weeks, 1-year nonrelapse mortality (NRM), and overall survival (OS). A previously validated algorithm of 2 MAGIC biomarkers (ST2 and REG3α) consistently separated steroid-resistant patients into 2 groups with dramatically different NRM and OS (P < .001 for all 3 cohorts). High biomarker probability, resistance to steroids, and GVHD severity (Minnesota risk) were all significant predictors of NRM in multivariate analysis. A direct comparison of receiver operating characteristic curves showed that the area under the curve for biomarker probability (0.82) was significantly greater than that for steroid response (0.68, P = .004) and for Minnesota risk (0.72, P = .005). In conclusion, MAGIC biomarker probabilities generated after 1 week of systemic treatment of GVHD predict long-term outcomes in steroid-resistant GVHD better than clinical criteria and should prove useful in developing better treatment strategies.

AB - Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid immunosuppression. Clinical response after 1 week of therapy often guides further treatment decisions, but long-term outcomes vary widely among centers, and more accurate predictive tests are urgently needed. We analyzed clinical data and blood samples taken 1 week after systemic treatment of GVHD from 507 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC), dividing them into a test cohort (n = 236) and 2 validation cohorts separated in time (n = 142 and n = 129). Initial response to systemic steroids correlated with response at 4 weeks, 1-year nonrelapse mortality (NRM), and overall survival (OS). A previously validated algorithm of 2 MAGIC biomarkers (ST2 and REG3α) consistently separated steroid-resistant patients into 2 groups with dramatically different NRM and OS (P < .001 for all 3 cohorts). High biomarker probability, resistance to steroids, and GVHD severity (Minnesota risk) were all significant predictors of NRM in multivariate analysis. A direct comparison of receiver operating characteristic curves showed that the area under the curve for biomarker probability (0.82) was significantly greater than that for steroid response (0.68, P = .004) and for Minnesota risk (0.72, P = .005). In conclusion, MAGIC biomarker probabilities generated after 1 week of systemic treatment of GVHD predict long-term outcomes in steroid-resistant GVHD better than clinical criteria and should prove useful in developing better treatment strategies.

KW - Journal Article

U2 - 10.1182/blood-2018-01-822957

DO - 10.1182/blood-2018-01-822957

M3 - SCORING: Journal article

C2 - 29545329

VL - 131

SP - 2846

EP - 2855

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 25

ER -